Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S.... Read More

Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza... Read More

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md. , Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc.... Read More

GAITHERSBURG, Md. , Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M ™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into... Read More

GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference. Conference Details: Fireside Chat Date: Wednesday, November 20, 2024 Time: 11:00 – 11:25 a.m. Greenwich Mean Time Location: London, United Kingdom Moderator: Roger Song, MD, CFA,... Read More

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivables Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and... Read More

GAITHERSBURG, Md. , Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the... Read More

GAITHERSBURG, Md. , Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024 . Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30... Read More

GAITHERSBURG, Md. , Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The clinical hold is due to a... Read More

GAITHERSBURG, Md. , Oct. 9, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of... Read More

Ruxandra Draghia-Akli , MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and... Read More

Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwide Novavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and older GAITHERSBURG, Md. , Sept. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company... Read More

GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 26 th Annual Global Investment Conference: Fireside Chat Date: Monday, September 9, 2024 Time: 3:30 – 4:00 p.m. Eastern Time (ET) Location: New York City, New York... Read More

Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19 GAITHERSBURG, Md. , Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax... Read More

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza... Read More

GAITHERSBURG, Md. , Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024 . Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m.... Read More

Novavax's COVID-19 vaccine would be the only protein-based option available in Canada , if authorized Novavax's filing is aligned with NACI, U.S. FDA, EMA and WHO recommendations on vaccine composition GAITHERSBURG, Md. , July 2, 2024 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its... Read More

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ - - Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine... Read More

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release post-authorization and... Read More

GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 6, 2024 Time: 12:30 – 12:55 p.m. Eastern Time (ET) Location: New York, NY Moderator: Roger Song, MD, CFA, Equity Research... Read More

Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder Representative on Board RALEIGH, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Shah Capital Management, Inc. (together with its affiliates, “Shah Capital,” “we” or “our”) collectively beneficially owns ~7.9% of the outstanding common stock... Read More

GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 15, 2024 Time: 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) Location: Encore Hotel in Las Vegas, NV Moderator: Alec Stranahan,... Read More

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-M TM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: $500 million upfront payment Approximately $70 million equity investment in Novavax Up to $700 million... Read More

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties Novavax is entitled to additional... Read More

GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024 . Details of the event and replay are as follows: Conference call details: Date: May 10, 2024 Time: 8:30 a.m. U.S. ET... Read More

Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three... Read More

Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the... Read More

GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.... Read More

GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44 th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston Marriott Copley Place in Boston, Massachusetts... Read More

Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023 Announced settlement with Gavi related to 2021 advance purchase agreement, removing financial uncertainty and... Read More

GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a close. "Novavax is pleased to have reached this agreement with Gavi as it... Read More

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024 . Details of the event and replay are as follows: Conference call details: Date:... Read More

GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42 th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST) Location: Westin St. Francis Hotel in San Francisco,... Read More

Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid ™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant,... Read More

Novavax launches Choose to Protect™ campaign to educate public about importance of updated COVID-19 vaccination Recent survey finds that 70% of Canadians believe in the value of COVID-19 vaccination; 74% want to select the COVID-19 vaccine they receive GAITHERSBURG, Md. , Dec. 13 , 2023 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the... Read More

Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted)... Read More

GAITHERSBURG, Md. , Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in... Read More

New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans John Trizzino appointed to new Chief Operating Officer role Mark Casey to join as Chief Legal Officer and Corporate Secretary GAITHERSBURG, Md. , Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M... Read More

GAITHERSBURG, Md. , Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference. Conference Details: Fireside Chat Date: Wednesday, November 15, 2023 Time: 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) Location: London Moderator: Roger Song, M.D., CFA, Equity... Read More

Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option Secured broad access to Novavax's COVID-19 vaccine in the U.S. R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch Anticipate Phase 3 COVID-19-Influenza Combination vaccine trial... Read More

GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023 . Details of the event and replay are as follows: Conference call details: Date: November 9, 2023... Read More

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU member states to bring its updated COVID-19 vaccine to those that have requested doses through the advance purchase agreement GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing... Read More

Pending a European Commission decision, Novavax's vaccine will be the only updated protein-based non-mRNA COVID-19 vaccine available in Europe for individuals aged 12 and older GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine... Read More

GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Singapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older. The Singapore Ministry of Health... Read More

Full authorization of prototype enables rapid authorization of updated Novavax COVID-19 vaccines in future GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has granted full marketing authorization for its... Read More

Novavax's updated COVID-19 vaccine is now available at a wide range of retailers, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid, Stop & Shop and Topco Novavax's vaccine is the only protein-based non-mRNA COVID-19 vaccine option in the U.S. Novavax's vaccine finder is available at us.novavaxcovidvaccine.com GAITHERSBURG, Md. , Oct. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing... Read More

GAITHERSBURG, Md. , Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15 , and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19. Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an... Read More

Partnership with HealthyWomen and actor, mother and business owner Nicole Ari Parker encourages people to get informed about the importance of COVID vaccination and vaccine options The Choose to Protect survey, conducted by The Harris Poll, found 85% of U.S. adults aged 45+ agree it is important to have a range of COVID vaccine options for themselves and their family 1 Only two in five survey respondents say they are highly... Read More

This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid Find Novavax's vaccine at us.novavaxcovidvaccine.com or vaccines.gov GAITHERSBURG, Md. , Oct. 3, 2023 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a... Read More

GAITHERSBURG, Md. , Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M ™ adjuvant, today announced that Novavax granted non-qualified stock options and restricted stock units to Ian Watkins , Executive Vice President and Chief Human Resources Officer, as a material inducement for their entry into employment with Novavax. These awards were... Read More

GAITHERSBURG, Md. , Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference: Fireside Chat Date: Monday, September 11, 2023 Time: 4:30 – 5:00 p.m. Eastern Daylight Time (EDT) Location: Lotte New York... Read More

Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3 Upon regulatory approval, Novavax's COVID vaccine would be the only protein-based non-mRNA vaccine option available in key markets for the fall season GAITHERSBURG, Md. , Aug. 22, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company... Read More

Second quarter total revenue of $424 million and net income of $58 million Executed new strategic partnering agreement with SK bioscience, including an equity investment of $85 million in Novavax at $13.00 per share, a 59% premium to the 90-day VWAP Negotiated up to $350 million in 2023 payments under amended Canada APA Initiated FDA submission for approval of our updated XBB COVID vaccine for the 2023 fall vaccination... Read More

GAITHERSBURG, Md. , Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its second quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Daylight Time (EDT) on Tuesday, August 8, 2023 . Details of the event and replay are as follows: Conference call details: Date: August 8, 2023... Read More

Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU Marketing Authorization includes use of Nuvaxovid™ as a primary series in individuals aged 12 and older and booster in adults Marketing Authorization provides regulatory foundation for future vaccine updates, including Fall vaccination campaign GAITHERSBURG, Md. , July 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX),... Read More

Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immune responses to XBB subvariants including XBB.1.5, XBB.1.16 and XBB.2.3 If authorized, Novavax's protein-based vaccine candidate would be... Read More

GAITHERSBURG, Md. , June 15, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M ™ adjuvant, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), originally scheduled to be held on June 15, 2023, to July 11, 2023 at 8:30 a.m., Eastern Time . On June 15, 2023 the Company convened its Annual... Read More

GAITHERSBURG, Md. , June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research. "We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique... Read More

GAITHERSBURG, Md. , June 1 , 2023 /PRNewswire/ -- Novavax, Inc . (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 8, 2023 Time: 9:00 – 9:25 a.m. Eastern Daylight Time (EDT) Location: New York, NY Moderator: Roger Song, M.D., CFA,... Read More

GAITHERSBURG, Md. , May 26, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European... Read More

GAITHERSBURG, Md. , May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12... Read More

Announced global restructuring and cost reduction initiative with expected 2024 full-year R&D and SG&A reduction of approximately 40% to 50% vs 2022 Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billion First quarter revenue reflects shift to seasonal demand pattern; on-track to deliver updated COVID vaccine for Fall season Announced positive Phase 2 topline results for COVID-Influenza Combination,... Read More

This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators For the stand-alone influenza vaccine candidate, HAI responses were 31 to 56% higher for all four influenza strains compared to Fluad ® , and were 44 to 89% higher for A strains compared... Read More

GAITHERSBURG, Md. , May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference. Conference Details: Fireside Chat Date: Thursday, May 11, 2023 Time: 10:00 – 10:30 a.m. Pacific Daylight Time (PDT) Location: Encore Hotel in Las Vegas, Nevada Moderator:... Read More

GAITHERSBURG, Md. , May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday , May 9, 2023. Details of the event and replay are as follows: Conference call details: Date: May 9, 2023 Time: 8:30 a.m. U.S. Eastern... Read More

GAITHERSBURG, Md. , April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC , April 3 to 6, 2023 , and the 33rd European Congress of Clinical Microbiology &... Read More

GAITHERSBURG, Md. , March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43 rd Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 8, 2023 Time: 9:50 – 10:20 a.m. Eastern Standard Time (EST) Location: Boston Marriott Copley Place in Boston,... Read More

GAITHERSBURG, Md. , March 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non-qualified stock option and restricted stock units to Elaine O'Hara , its newly appointed Chief Strategy Officer, as a material inducement for her entry into employment with Novavax, effective as of March 1, 2023 (the... Read More

Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive Officer Updated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023 Expanded Nuvaxovid™ label in adult booster and adolescent primary series Initiated Phase 2 trial of COVID-19-Influenza Combination and... Read More

GAITHERSBURG, Md. , Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023 , following the close of U.S. financial markets. Details of the event and replay are as follows: Conference... Read More

Modified agreement also includes the development of an updated vaccine in fall 2023 GAITHERSBURG, Md. , Feb. 13, 2023 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the... Read More

GAITHERSBURG, Md. , Jan. 25, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs , its newly appointed President and Chief Executive Officer, as a material inducement for his entry into... Read More

GAITHERSBURG, Md. , Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) for use as a booster for active... Read More

Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline development GAITHERSBURG, Md. , Jan. 9, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and... Read More

GAITHERSBURG, Md. , Dec. 30, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates. The dose-confirming trial will evaluate the safety and effectiveness... Read More

GAITHERSBURG, Md. , Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022 , Novavax, Inc. (Nasdaq: NVAX) , a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027 (the "Notes"), and on December 23,... Read More

GAITHERSBURG, Md. , Dec. 15, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX) , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In connection with... Read More

GAITHERSBURG, Md. , Dec. 15, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX) , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the "notes"). The notes are being offered and sold only to persons reasonably believed to be... Read More

GAITHERSBURG, Md. , Dec. 14, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to... Read More

GAITHERSBURG, Md. , Dec. 14, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the "notes"). The notes will be offered and sold only to persons reasonably believed to be qualified... Read More

GAITHERSBURG, Md. , Dec. 7, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease... Read More

GAITHERSBURG, Md. , Dec. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of... Read More

GAITHERSBURG, Md. , Nov. 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019... Read More

GAITHERSBURG, Md. , Nov. 18, 2022 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused... Read More